Amneal Pharmaceuticals announced it has submitted Abbreviated New Drug Applications to the U.S. Food and Drug Administration for three key complex generic products, including: IQVIA, Albuterol sulfate inhalation Bimatoprost ophthalmic solution, Propofol emulsion ..”We continue to make excellent progress advancing our pipeline of complex, high-value medicines. The filing of applications for three new complex generics are additional proof points in our successful innovation journey. Today, about 90% of our generics R&D pipeline is made up of complex products. As we move up the value chain of product complexity, we are adding new and sustainable long-term growth drivers to our diversified portfolio,” said Chirag and Chintu Patel, Co-Chief Executive Officers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRX:
- Amneal (NYSE: AMRX) Tanks after Receiving Complete Response Letter from the U.S. FDA
- Amneal Complete Response Letter a surprise, says Barclays
- Amneal Pharmaceuticals announces launch of authorized generic for Xyrem
- Amneal Pharmaceuticals receives FDA Complete Response Letter for IPX203
- Amneal receives NDA approval from FDA for PEMRYDI RTU injectable